Biogen Inc
Biogen beats expectations, hikes outlook as Alzheimer’s drug Leqembi and other new products gain traction
A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021. Dado Ruvic | Reuters Biogen on Thursday reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance, as the company’s cost cuts showed progress and sales of its breakthrough Alzheimer’s drug, Leqembi, and […]
Read More
GEHC gives reasons to look beyond temporary China woes and shares reverse higher
GE Healthcare on Wednesday morning reported a mixed second quarter and shares initially moved sharply lower. The stock then reversed higher as the post-earnings call got underway. Management made it clear that they think that weakness in China is temporary and see many other levers available to grow earnings. Revenue advanced less than 1% year over […]
Read More
Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says
The newly FDA approved Alzheimer’s treatment Leqembi is prepared at Abington Neurological Associates in Abington, PA., on Tuesday, November 7, 2023. Hannah Yoon | The Washington Post | Getty Images The breakthrough Alzheimer’s drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term, […]
Read More
Older GLP-1 drug from Novo Nordisk may slow Alzheimer’s disease progression by protecting the brain, study says
A box of the drug Victoza, made by Novo Nordisk Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020. George Frey | Reuters An older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer’s disease by protecting patients’ brains, according to data […]
Read More
European drug regulator rejects Alzheimer’s treatment Leqembi from Biogen, Eisai
European drug regulators on Friday rejected the Alzheimer’s treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S. The European Commission, the EU’s executive body, has a final say in Leqembi’s approval. But it almost always follows the drug regulator’s recommendations. […]
Read More
Investors want proof AI will aid drug discovery. Evidence may come in the second half
As investors peer into the future to envision which industries are ripe to be reshaped and energized by artificial intelligence, drug discovery is fast emerging as an obvious choice. Each new drug that hits the market is the product of billions of dollars in investment, often taking at least a decade to get there. The […]
Read More
FDA approval of Eli Lilly’s Alzheimer’s drug cements our decision not to take profits
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Rally in markets: Stocks were higher across the board Tuesday afternoon, led by the Nasdaq Composite , which added 0.7% and was on pace for back-to-back […]
Read More
Eli Lilly assures investors it can overcome the high-quality problem of too much demand
Eli Lilly ‘s raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly success story remains intact, as demand for its new diabetes and obesity drugs, Mounjaro and Zepbound, outstrips supply. Revenue in the three months ended March […]
Read More
Stocks making the most important moves midday: Tesla, Hilton, Boeing, Mattel and more
Examine out the companies building headlines in midday buying and selling: Boeing — The aerospace big fell 1.5% even after noting that it burned as a result of $3.9 billion in money in the first quarter. The funds melt away was lessen than what analysts had feared. Boeing also posted an adjusted decline of $1.13 […]
Read More
Shares creating the greatest moves premarket: Boeing, Tesla, Visa, Airbnb and far more
Look at out the companies generating headlines right before the bell. Boeing — Shares jumped 3% soon after Boeing posted a narrower-than-expected loss in its latest results. In its first quarter, the firm reported an altered decline of $1.13 for every share, far better than the modified loss of $1.76 per share estimated by the […]
Read More